ProShare Advisors
HRMY icon

ProShare Advisors’s Harmony Biosciences HRMY Stock Holding History

ProShare Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$301K Sell
8,280
-1,072
-11% -$33.8K ﹤0.01% 1413
2026
Q1 		$262K Sell
9,352
-1,641
-15% -$53.8K ﹤0.01% 1405
2025
Q4 		$411K Buy
10,993
+774
+8% +$25.4K ﹤0.01% 1248
2025
Q3 		$282K Sell
10,219
-1,593
-13% -$54.9K ﹤0.01% 1473
2025
Q2 		$373K Buy
11,812
+247
+2% +$7.95K ﹤0.01% 1290
2025
Q1 		$384K Sell
11,565
-2,625
-18% -$94.1K ﹤0.01% 1243
2024
Q4 		$488K Buy
14,190
+4,534
+47% +$156K ﹤0.01% 1285
2024
Q3 		$386K Buy
9,656
+1,197
+14% +$42K ﹤0.01% 1301
2024
Q2 		$255K Sell
8,459
-2,029
-19% -$61K ﹤0.01% 1401
2024
Q1 		$352K Buy
10,488
+684
+7% +$22K ﹤0.01% 1317
2023
Q4 		$317K Buy
9,804
+850
+9% +$23.7K ﹤0.01% 1336
2023
Q3 		$293K Buy
8,954
+2
+0% +$69 ﹤0.01% 1217
2023
Q2 		$315K Buy
8,952
+924
+12% +$31.9K ﹤0.01% 1245
2023
Q1 		$262K Sell
8,028
-1,116
-12% -$50.8K ﹤0.01% 1284
2022
Q4 		$504K Buy
9,144
+471
+5% +$25.9K ﹤0.01% 960
2022
Q3 		$384K Buy
8,673
+467
+6% +$22.8K ﹤0.01% 1012
2022
Q2 		$400K Sell
8,206
-2,990
-27% -$135K ﹤0.01% 1040
2022
Q1 		$544K Sell
11,196
-2,772
-20% -$113K ﹤0.01% 1234
2021
Q4 		$595K Buy
+13,968
New +$557K ﹤0.01% 1337

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ProShare Advisors's HRMY Position: Q2 2026 in Review

ProShare Advisors reduced its Harmony Biosciences (HRMY) stake by 11% in Q2 2026, selling an estimated $33.8K and leaving 8,280 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #1413.

ProShare Advisors first reported a position in HRMY in Q4 2021 and has held it in 19 quarters since. The position peaked at $595K in Q4 2021. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • ProShare Advisors held 8,280 shares of Harmony Biosciences worth $301K as of Q2 2026.
  • ProShare Advisors sold 1,072 Harmony Biosciences shares in Q2 2026, an estimated $33.8K.
  • Harmony Biosciences made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1413 holding.
  • ProShare Advisors first reported a position in Harmony Biosciences in Q4 2021 and has held it in 19 quarters since.
  • ProShare Advisors's Harmony Biosciences position peaked at $595K in Q4 2021.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.